Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

Treatment Advances in HR+ Breast Cancer

March 19th 2021

A panel of experts who treat breast cancer close out a discussion on the use of newer therapies, including CDK4/6 inhibitors, based on outcomes demonstrated by recent clinical trials.

Case Discussion 2: Systemic Therapy for ER+, PR+, HER2- Breast Cancer

March 19th 2021

Breast oncologists review the appropriateness for treating a patient with ER-positive, PR-positive, HER2-negative breast cancer with systemic therapy, with special considerations regarding sequencing therapy if using a CDK4/6 inhibitor as adjuvant therapy.

The PRIME II Study in HR+ Breast Cancer

March 19th 2021

Andrew Seidman, MD, comments on results of the PRIME II study presented at SABCS and the appropriateness for radiation therapy in certain patient populations with HR-positive breast cancer.

The PENELOPE-B Study in HR+ Breast Cancer

March 12th 2021

Dr Massimo Cristofanilli, of the Feinberg School of Medicine, describes the PENELOPE-B study of palbociclib and endocrine therapy for patients with HR-positive breast cancer at high risk of relapse after neoadjuvant chemotherapy.

Updated Results of MonarchE in HR+ Breast Cancer

March 12th 2021

Dr Sara Tolaney comments on recent updates of the monarchE trial of abemaciclib and adjuvant endocrine therapy for high-risk early stage breast cancer as presented at SABCS 2020.

Rationale for Ovarian Suppression in HR+ Breast Cancer

March 5th 2021

During a discussion regarding data demonstrated by the RxPONDER trial in HR-positive breast cancer, breast oncologists consider when ovarian suppression is most appropriate and for whom.

Results of RxPONDER in HR+ Breast Cancer

March 5th 2021

Dr Andrew Seidman reacts to outcomes of the RxPONDER trial of chemotherapy use in women with HR-positive breast cancer at low risk of recurrence.

Early-Stage HR+ Breast Cancer: Treatment Options

February 26th 2021

Risk of Recurrence in Early-Stage HR+ Breast Cancer

February 26th 2021

HR+ MBC: Resistance to CDK4/6 Inhibitors

February 19th 2021

Targeting the PI3K/AKT/mTOR Pathway in HR+ MBC

February 19th 2021

Treating HR+ MBC After Frontline CDK4/6 Therapy

February 12th 2021

Treating PIK3CA Mutations in HR+ MBC

February 12th 2021

Case Discussion 1: Resistance to a CDK4/6 Inhibitor

February 5th 2021

CDK4/6 Inhibitors for HR+ MBC: Data and Utilization

February 5th 2021

Frontline Therapy for HR+ MBC: CDK4/6 Inhibitors

January 29th 2021

Evaluating Tumor Biology in HR+ Metastatic Breast Cancer

January 29th 2021

Future Directions for Treatment of TNBC

October 23rd 2020

Phase 3 ASCENT Trial in mTNBC: Managing Adverse Events

October 23rd 2020

Phase 3 ASCENT Trial in mTNBC

October 23rd 2020